X4 Pharmaceuticals, Inc
XFOR Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$3.25
KIRA · Stoqly’s AI analyst, in plain words
- X4 Pharmaceuticals, Inc had $6.5M of revenue in fiscal 2025, up 150.0% on the year before. Over five years, revenue changed +16.7% a year on average.
- Its operating margin was −1,336.7%, up 63.4 pts: of every 100 in sales, about −1,337 is left after running the business.
- X4 Pharmaceuticals, Inc lost $79.2M in fiscal 2025.
- Free cash flow was −$85.6M in fiscal 2025, −1,317.2% of revenue.
- X4 Pharmaceuticals, Inc has $142M more cash than debt.
Market cap
$411M
P/E
2.6x
Revenue
$6.5M
Net income
−$79.2M
Free cash flow
−$85.6M
Operating margin
−1,336.7%
X4 Pharmaceuticals, Inc in 30 seconds · fiscal 2025
Are sales growing?
+150.0%
Yes. Sales grew 150.0% last year.
Does it make a profit?
−1,218.4%
No. It lost money last year.
Does profit turn into cash?
−1,317.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
2.6x
One share costs 2.6 times its yearly profit per share.
What X4 Pharmaceuticals, Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- X4 Pharmaceuticals, Inc
- CIK
- 0001501697
X4 Pharmaceuticals, Inc · XFOR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $2.6M | $6.5M |
| Revenue growth | −100.0% | — | — | — | 150.0% |
| Gross margin | — | — | — | 69.3% | 11.4% |
| Operating margin | — | — | — | −1,400.0% | −1,336.7% |
| Net income | −$88.7M | −$93.9M | −$101M | −$37.5M | −$79.2M |
| Net margin | — | — | — | −1,440.4% | −1,218.4% |
| Diluted EPS | −$3.99 | −$1.52 | −$17.07 | −$5.59 | −$1.87 |
| Cash | |||||
| Cash from operations | −$70.9M | −$77.1M | −$96.5M | −$131M | −$85.6M |
| Capital expenditure | $0.6M | $0.1M | $0.1M | $0.3M | $0.0M |
| Free cash flow | −$71.5M | −$77.2M | −$96.6M | −$131M | −$85.6M |
| FCF margin | — | — | — | −5,047.2% | −1,317.2% |
| Share buybacks | $2.0M | $0.0M | $0.0M | — | — |
| Share count change | 28.3% | 146.7% | −90.7% | 13.1% | 531.0% |
| Debt and strength | |||||
| Cash and short-term investments | $81.8M | $122M | $99.2M | $55.7M | $217M |
| Debt incl. finance leases | $32.5M | $32.5M | $55.0M | $75.0M | $75.0M |
| Shareholders' equity | $64.4M | $74.1M | $51.1M | $22.1M | $186M |
| Current ratio | 6.3x | 5.8x | 5.3x | 3.4x | 10.2x |
| Interest coverage | −23.4x | −21.9x | −18.6x | −4.2x | −9.8x |
| Returns and quality | |||||
| Return on capital | −444.5% | — | −1,234.1% | −69.4% | −155.1% |
| Return on equity | −129.3% | −135.6% | −161.7% | −102.3% | −76.0% |
| Return on tangible equity | −218.1% | −170.0% | −299.8% | — | −49.6% |
| Piotroski F-score | 1 | 3 | 2 | 2 | 3 |
| Altman Z'' | −7.3 | −6.2 | −10.5 | −9.4 | −1.5 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.5M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
X4 Pharmaceuticals, Inc · XFOR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.25 a share, the company is worth $411M: 2.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001501697). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.